Monoclonal antibodies directed to the HER2 receptor
First Claim
Patent Images
1. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, at an antibody concentration on of 0.5-30 μ
- g/ml, wherein said SK-BR-3 cells are cultured in culture medium comprising 10% fetal bovine serum and said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
1 Assignment
0 Petitions
Accused Products
Abstract
Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
-
Citations
39 Claims
-
1. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, at an antibody concentration on of 0.5-30 μ
- g/ml, wherein said SK-BR-3 cells are cultured in culture medium comprising 10% fetal bovine serum and said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
- View Dependent Claims (2, 3)
-
4. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to TNF-α
- , and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20% at an antibody concentration on of 0.5-3.0 μ
g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
- , and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20% at an antibody concentration on of 0.5-3.0 μ
-
5. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to cisplatin, and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, at an antibody concentration of 0.5-3.0 μ
- g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
-
6. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to doxorubicin, and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20% at an antibody concentration, of 0.5 -3.0 μ
- g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
-
7. A monoclonal antibody which binds to the HER2 receptor epitope to which monoclonal antibody 4D5 (ATCC CRL 10463) binds.
- 8. A monoclonal antibody which has the identifying biological characteristics of monoclonal antibody 4D5 (ATCC CRL 10463).
- 10. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and sensitizes tumor cells to TNF-α
- 36. A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and sensitizes tumor cells to cisplatin or doxorubicin.
Specification